<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3011234569
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Bleomycin Venus
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BLEOMYCIN SULFATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        USP Units
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        63.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VENUS REMEDIES LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VENUS REMEDIES LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            VENUS REMEDIES LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01DC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine contains the active ingredient bleomycin sulphate. Bleomycin Venus is one of a group of medicines called cytostatic medicines. These medicines are anti-cancer medicines sometimes referred to as chemotherapy. They attack cancer cells and prevent them from dividing.</p><p>&nbsp;</p><p>Bleomycin Venus is used to treat:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain types of cancer (squamous cell carcinomas) in the head and neck, cervix and external genitalia;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain types of lymph node cancer (e.g. Hodgkin&#39;s disease and Non-Hodgkin&rsquo;s lymphoma of intermediate and high malignancy);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Testicular cancer;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid accumulation in the lungs (as a result of cancer).</p><p>&nbsp;</p><p>Bleomycin Venus can be used alone, or in combination with other cancer medications, and/or in combination with radiotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Bleomycin Venus:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to bleomycin sulphate or to any similar anti-cancer medicine;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have Ataxia telangiectasia (very rare inherited disease that leads to difficulties in coordinating your movements and the risk of infections).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an acute lung infection or severe lung impairment;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of lung damage (possibly) caused by bleomycin;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; during breast-feeding (see also &quot;Pregnancy and lactation&quot; section).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist or nurse before using Bleomycin Venus if:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are over 60 years of age;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your kidneys or liver no longer function properly;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have had a lung disease;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you had lung irradiation prior to bleomycin treatment, or if you are having radiation therapy during bleomycin treatment;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have chickenpox</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are being administered oxygen. Tell your doctor that you are using bleomycin</p><p>&nbsp;</p><p>You must also tell your doctor if you have an operation planned as it may be necessary to adjust your treatment with bleomycin Venus.</p><p>&nbsp;</p><p>The patient groups specified above are more sensitive to bleomycin&#39;s harmful effects on the lungs. The doctor will probably examine you more often and/or take X-rays of your lungs. If you are treated with bleomycin, a regular lung function test should be performed, to monitor the possible adverse effects of</p><p>bleomycin on the lungs.</p><p>If you have a cough and/or are short of breath, this can be a sign of the adverse effects of bleomycin on the lungs. In this case you should inform a doctor immediately.</p><p>&nbsp;</p><p>Like other cytotoxic active substances, bleomycin can trigger tumour lysis syndrome in patients with rapidly growing tumours. Appropriate supportive treatment and pharmacological measures might prevent or alleviate such complications.</p><p>&nbsp;</p><p><strong>Other medicines and Bleomycin Venus</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>An interaction is taken to refer to when (medicinal) products used together may influence each other&#39;s efficacy and/or side effects. An interaction may occur when bleomycin Venus is used together with:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carmustine, mitomycin, cyclophosphamide, gemcitabine (medicines used for certain types of cancer) and methotrexate (a medicine used for certain types of cancer, rheumatism and severe skin diseases): there is an increased risk of harmful effects on the lungs;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisplatin (an anti-cancer medicine) and other medicines that cause kidney damage: there is an increased risk of side effects from bleomycin (potentiation of pulmonary toxicity);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vinca alkaloids (a group of medicinal products used for certain types of cancer, e.g. vincristine, vinblastine): circulatory disturbances may occur in the extremities (fingers, toes, tip of the nose). In very severe cases the extremities can die (necrosis);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acetyldigoxin (a medicine for cardiac disorders): there is a risk that the effect of acetyldigoxin will be reduced;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin (a medicine for epilepsy): there is a risk that the effect of phenytoin will be reduced;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clozapine (a medicine for schizophrenia): it may cause more severe reduction in number of white blood cells which makes infections more likely.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Radiotherapy: the risk of side effects on the lungs and/or mucous membranes is increased;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen: you are at greater risk of pulmonary toxicity if you are given oxygen during anaesthesia;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gentamicin, amikacin and ticarcillin (medicines that inhibit the growth of bacteria): the efficacy of these substances may be reduced;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciclosporine and tacrolimus (medicines that reduce efficacy of immune system): risk of excessive generation of lymphocytes.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Granulocyte colony-stimulating factor: lung damage may be aggravated;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Live vaccines: there is a risk of serious or life-threatening infections caused by the vaccine. Vaccinations with live vaccines should therefore not be administered to patients receiving bleomycin.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><u>Pregnancy</u></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning<u> </u>to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Animal studies have shown that this medicine can harm the embryo.</p><p>The use of Bleomycin Venus should be avoided during pregnancy, especially during the<u> </u>first 3 months.</p><p>If Bleomycin Venus treatment is vital during the first three months of pregnancy, a<u> </u>medical consultation on aborting the pregnancy is essential.</p><p>&nbsp;</p><p>Both men and women must take measures to prevent a pregnancy during use of Bleomycin Venus, and for 6 months after the end of the treatment. If pregnancy occurs during treatment with Bleomycin Venus, genetic counselling is recommended.</p><p>&nbsp;</p><p>Men who wish to father children in the future should seek advice on storing sperm before starting treatment with Bleomycin Venus because there is possibility of becoming irreversibly infertile by the treatment.</p><p>&nbsp;</p><p><u>Breast feeding </u></p><p>It is not known whether Bleomycin Venus or the metabolically degraded materials are secreted in your milk, but since there is a possibility that Bleomycin Venus is harmful to your child, you must not breast-feed during treatment with Bleomycin Venus.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Bleomycin Venus therapy may cause irreversible infertility.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>This medicinal product may affect your reactions and your ability to drive.<strong> </strong></p><p><strong>&nbsp;</strong></p><p>Possible side effects of chemotherapy with Bleomycin Venus may occur, such as<strong> </strong>nausea and vomiting. If you are affected by these side effects, you should not<strong> </strong>drive and/or operate machines that require you to be alert.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The doctor will calculate the required quantity for you, based on the dosage details specified later.</p><p><u>&nbsp;</u></p><p><u>The usual dose:</u></p><p>The (total) dose depends on the indication, your age, renal function, and combination with other anticancer medicines. Your doctor will set the dose of Bleomycin Venus, the duration of the treatment, and the number of treatments. These can vary for each patient.</p><p>&nbsp;</p><p>There is a risk of serious hypersensitivity reaction especially in lymphoma patients which may occur directly or sometime after administration. Therefore, your doctor will give you a test dose and will observe for 4 hours before starting Bleomycin Venus therapy for the first time.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Your doctor will administer Bleomycin Venus into a vein or artery, under the skin, into a muscle, directly into the tumour, or into the space surrounding the lungs (intrepleural), either by injection or using an infusion.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>There is insufficient experience with regard to the administration of Bleomycin Venus in children and adolescents.</p><p>Until more information is available, Bleomycin Venus should only be administered in children and adolescents in exceptional circumstances and at special facilities.</p><p>&nbsp;</p><p><strong>If you take more Bleomycin Venus than you should</strong></p><p>Symptoms that can occur if you have received too much bleomycin include: low blood pressure, fever, increased heart rate and shock. If you notice any of the above symptoms, please tell your doctor, who will arrange for the appropriate treatment. Use of the medicinal product must be discontinued immediately.</p><p>&nbsp;</p><p>Information for the doctor:</p><p>Information about treating an overdose can be found at the end of this leaflet.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Bleomycin Venus </strong></p><p>If you have missed an injection, please talk with your treating doctor, to clarify if and how to make up for the missed dose.</p><p>&nbsp;</p><p><strong>If you stop taking Bleomycin Venus</strong></p><p>If you suddenly stop taking Bleomycin Venus without consulting a doctor, the original symptoms may recur.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Bleomycin Venus can cause immediate and delayed side effects. Fever on the day of injection is the earliest reaction. Loss of appetite, loss of hair, chills, fatigue, inflammation of the lungs (interstitial pneumonia) &ndash; shortness of breath or cough, inflammation of the mucous lining of the mouth and nausea may also occur. Pain at the injection site and in the tumour area has also been observed on occasion. Other sporadic side effects include a fall in blood pressure and local thrombophlebitis (inflammation of a vein) after administration into a vein.</p><p>Skin and mucosal lesions are the most common side effects and are observed in up to 50 % of the patients treated. They comprise redness; rash; itching; formation of ulcers, stretch marks and blisters; heavy pigmentation; and tenderness and swelling of the fingertips.</p><p>&nbsp;</p><p><strong>Serious side effects:</strong></p><p>If you develop any of the following side effects, tell your doctor immediately:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coughing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathlessness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cracking or popping sound when breathing</p><p>&nbsp;</p><p>You may need to have your treatment stopped.</p><p>&nbsp;</p><p>Side effects can include the following:</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10 patients)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; interstitial pneumonitis (inflammatory changes in the lungs)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pulmonary fibrosis (disease of the lung tissue caused by increased formation of connective tissue between the alveoli)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; laboured breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea and vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mucositis (inflammation of the mucous membranes)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomatitis (inflammation of the mucous lining of the mouth)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammatory redness of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; striae (stretch marks)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blistering</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperpigmentation (increased pigment formation)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tenderness and swelling of the fingertips</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperkeratosis (excessive thickening of the skin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe hypersensitivity reactions. These reactions may occur immediately, or after a delayed period of a few hours after the first or second dose. Tell your doctor straight away if you get any sudden wheeziness, difficulty in breathing, swelling of the eyelids, face or lips, rash or itching (especially affecting your whole body). idiosyncratic reaction (various types of hypersensitivity reaction)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute respiratory insufficiency (acute respiratory distress syndrome - ARDS)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pulmonary embolism</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, urticaria, erythema</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; induration (hardening of the skin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swellings (due to fluid retention in the tissues)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammatory skin reaction</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pyrexia, chills and malaise</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; myelosuppression (damage to the bone marrow)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leukopaenia (reduction in white blood cell count)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neutropaenia (reduction in neutrophil granulocytes in the blood)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrombocytopaenia (reduction in platelets)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haemorrhage (bleeding)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angular cheilitis (infection of the corners of the mouth) and diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deformation and discolouration of the nails, bulla formation at pressure points</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle and joint pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oliguria (decreased urine output)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain during urination</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; polyuria (increased urine volume)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary retention</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the tumour area</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phlebitis (inflammation of a vein)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypertrophy (thickening) of the vein wall and venous access constriction (with i.v. administration)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; induration (hardening of the tissue following administration into a muscle or with local administration)</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropaenic fever (fever caused by a decrease in white blood cells)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack, pericarditis (inflammation of the fibrous sac surrounding the heart) and chest pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cerebral infection, thrombotic microangiopathy (disease of the capillaries and arterioles), haemolytic uraemic syndrome (severe disease affecting the blood and kidneys)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cerebral arteritis (inflammation of the small and medium-sized arteries in the brain)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raynaud&#39;s phenomenon (a vascular disorder), arterial thrombosis, deep vein thrombosis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hepatic impairment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; scleroderma (hardening of the connective tissue)</p><p>&nbsp;</p><p><strong>Vary rare</strong> (may affect up to 1 in 10,000 people)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumour lysis syndrome (condition following rapid breakdown of tumours)</p><p>&nbsp;</p><p><strong>Not Known</strong> (frequency cannot be estimated from the available data)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overwhelming infection (sepsis),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe reduction in blood cells (pancytopenia),</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in red blood cells (anaemia),</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</strong></p><p>&bull; The National Pharmacovigilance Centre (NPC):<br />&minus; SFDA Call Center: 19999<br />&minus; E-mail: npc.drug@sfda.gov.sa<br />&minus; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and the vial after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>&nbsp;</p><p>For single use only. Discard any residues.</p><p>&nbsp;</p><p>The reconstituted/diluted product should be used immediately.</p><p>&nbsp;</p><p>Do not use this medicine if you notice any visible signs of deterioration in the product or the vial, e.g. discolouration of the powder or damage to the vial and the seal.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp; The active substance is bleomycin sulfate.</p><p>&bull;&nbsp; The other ingredient is mannitol and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Bleomycin Venus is White or cream-colored, lyophilized mass filled in 5 ml colorless glass vials close with rubber stopper sealed with a flip-off aluminium seal.
1 vial/pack

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Venus Remedies Limited</p><p>Hill Top Industrial Estate, Jharmajri EPIP,</p><p>Phase-I (Extn.), Bhatoli Kalan, Baddi, Distt. Solan, Himachal Pradesh, 173205</p><p>India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in June 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي هذا الدواء على المادة الفعالة من سلفات البليوميسين. بليومايسين فينوس هو واحد من مجموعة من الأدوية تسمى الأدوية المثبطة للخلايا. هذه الأدوية هي أدوية مضادة للسرطان يشار إليها أحيانًا بالعلاج الكيميائي. فهي تهاجم الخلايا السرطانية وتمنعها من الانقسام.</p><p>&nbsp;</p><p dir="RTL">يستخدم بليومايسين فينوس لعلاج:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنواع معينة من السرطان (سرطان الخلايا الحرشفية) في الرأس والرقبة وعنق الرحم والأعضاء التناسلية الخارجية؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنواع معينة من سرطان العقدة الليمفاوية (مثل مرض هودجكين وسرطان الغدد الليمفاوية اللاهودجكين من الأورام الخبيثة المتوسطة والعالية)؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الخصية؛</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تراكم السوائل في الرئتين (نتيجة الإصابة بالسرطان).</p><p>&nbsp;</p><p dir="RTL">يمكن استخدام بليومايسين فينوس بمفرده، أو مع أدوية السرطان الأخرى ، و / أو مع العلاج الإشعاعي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم بليومايسين فينوس في الحالات التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه كبريتات البليوميسين أو أي دواء مماثل مضاد للسرطان؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك توسع الشعريات (مرض وراثي نادر جدًا يؤدي إلى صعوبات في تنسيق حركاتك وخطر الإصابة بالعدوى).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من التهاب رئوي حاد أو ضعف شديد في الرئة؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك سجل مرضي من تلف الرئة (ربما) الناجم عن البليوميسين؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أثناء الرضاعة الطبيعية (أنظري أيضًا قسم &quot;الحمل والرضاعة&quot;).</p><p>&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل استخدام بليومايسين فينوس في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجاوز عمر 60 عامًا؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم تعد تعمل الكليتان أو الكبد بشكل صحيح؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك أو كان لديك مرض رئوي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت للإشعاع في الرئة قبل العلاج بالبليوميسين، أو إذا كنت تخضع للعلاج الإشعاعي أثناء العلاج بالبليوميسين؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من جدري الماء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاؤك الأكسجين. أخبر طبيبك بأنك تستخدم البليوميسين</p><p>&nbsp;</p><p dir="RTL">يجب عليك أيضًا إخبار طبيبك إذا كنت تنوي إجراء عملية جراحية لأنه قد يكون من الضروري تعديل خطة علاجك بالبليومايسين فينوس.</p><p>&nbsp;</p><p dir="RTL">مجموعات المرضى المحددة أعلاه أكثر حساسية للتأثيرات الضارة للبليوميسين على الرئتين. من المحتمل أن يفحصك الطبيب في كثير من الأحيان و / أو يأخذ أشعة سينية لرئتيك. إذا كنت تعالج بالبليوميسين، فيجب إجراء اختبار منتظم لوظائف الرئة، لمراقبة الآثار الضارة المحتملة</p><p dir="RTL">للبليوميسين على الرئتين.</p><p dir="RTL">إذا كنت تعاني من السعال و/أو ضيق التنفس ، فقد يكون ذلك علامة على الآثار الضارة للبليوميسين على الرئتين.&nbsp; في هذه الحالة يجب إبلاغ الطبيب على الفور.</p><p>&nbsp;</p><p dir="RTL">مثل المواد الفعالة الأخرى السامة للخلايا، يمكن أن يؤدي البليوميسين إلى متلازمة تحلل الورم في المرضى الذين يعانون من أورام سريعة النمو. العلاج الداعم المناسب والتدابير الدوائية قد تمنع أو تخفف من مثل هذه المضاعفات.</p><p>&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وبليومايسين فينوس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تستخدم أو استخدمت مؤخرًا أو ربما تستخدم أي أدوية أخرى.</p><p dir="RTL">يتم الاسترشاد بالتفاعل للإشارة إلى متى قد تؤثر المنتجات (الطبية) المستخدمة معًا على فعالية بعضها البعض و / أو الآثار الجانبية. قد يحدث تفاعل عند استخدام بليومايسين فينوس مع:</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كارموستين، وميتوميسين، وسيكلوفوسفاميد، وجيمسيتابين (أدوية تستخدم لأنواع معينة من السرطان) وميثوتريكسات (دواء يستخدم لأنواع معينة من السرطان والروماتيزم وأمراض الجلد الحادة): هناك خطر متزايد للتأثيرات الضارة على الرئتين؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسبلاتين (دواء مضاد للسرطان) وأدوية أخرى تسبب تلف الكلى: هناك خطر متزايد من الآثار الجانبية من بليوميسين (تقوية السمية الرئوية)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلويدات الفينكا (مجموعة من الأدوية المستخدمة لأنواع معينة من السرطان، مثل فينكريستين، فينبلاستين): قد تحدث اضطرابات في الدورة الدموية في الأطراف (أصابع اليدين، أصابع القدم ، طرف الأنف).&nbsp; في الحالات الشديدة للغاية يمكن أن تموت الأطراف (نخر)؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أسيتيلديجوكسين (دواء لاضطرابات القلب): هناك خطر يتمثل في انخفاض تأثير الأسيتيلديجوكسين؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين (دواء لعلاج الصرع): هناك خطر يتمثل في انخفاض تأثير الفينيتوين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلوزابين (دواء لمرض انفصام الشخصية): قد يسبب انخفاضًا حادًا في عدد خلايا الدم البيضاء مما يزيد من احتمالية الإصابة بالعدوى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج الإشعاعي: يزداد خطر الآثار الجانبية على الرئتين و/أو الأغشية المخاطية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأكسجين: تكون أكثر عرضة للإصابة بالتسمم الرئوي إذا تم إعطاؤك الأكسجين أثناء التخدير؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجنتاميسين والأميكاسين والتيكارسيللين (الأدوية التي تثبط نمو البكتيريا): قد تنخفض فعالية هذه المواد؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين وتاكروليموس (الأدوية التي تقلل من فعالية الجهاز المناعي): خطر التوليد المفرط للخلايا الليمفاوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عامل تحفيز مستعمرة المحببات: قد يتفاقم تلف الرئة؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اللقاحات الحية: هناك خطر الإصابة بعدوى خطيرة أو مهددة للحياة بسبب اللقاح.&nbsp; لذلك لا ينبغي إعطاء التطعيمات بلقاحات حية للمرضى الذين يتناولون بليوميسين.</p><p>&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">إذا كنت حاملًا أو مرضعة، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، فاسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">أظهرت الدراسات التي أجريت على الحيوانات أن هذا الدواء يمكن أن يضر بالجنين.</p><p dir="RTL">يجب تجنب استخدام بليومايسين فينوس أثناء الحمل، خاصة خلال الأشهر الثلاثة الأولى.</p><p dir="RTL">إذا كان علاج بليومايسين فينوس أمرًا مهمًا خلال الأشهر الثلاثة الأولى من الحمل، فإن الاستشارة الطبية حول إجهاض الحمل ضرورية.</p><p>&nbsp;</p><p dir="RTL">يجب على كل من الرجال والنساء اتخاذ تدابير لمنع الحمل أثناء استخدام بليومايسين فينوس ولمدة 6 أشهر بعد انتهاء العلاج.&nbsp; إذا حدث الحمل أثناء العلاج باستخدام بليومايسين فينوس، فيوصى بالاستشارة الوراثية.</p><p>&nbsp;</p><p dir="RTL">يجب على الرجال الذين يرغبون في إنجاب أطفال في المستقبل أن يطلبوا المشورة بشأن تخزين الحيوانات المنوية قبل بدء العلاج باستخدام بليومايسين فينوس لأن هناك احتمال أن يصابوا بالعقم الدائم بسبب العلاج.</p><p>&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية </u></p><p dir="RTL">من غير المعروف ما إذا كان يتم فرز بليومايسين فينوس أو المواد المتحللة الأيضية في حليبك، ولكن نظرًا لوجود احتمال أن يكون بليومايسين فينوس ضارًا لطفلك، فيجب عليك عدم الرضاعة الطبيعية أثناء العلاج باستخدام بليومايسين فينوس.</p><p>&nbsp;</p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">قد يسبب علاج بليومايسين فينوس عقمًا دائمًا</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستعمال الماكنات </strong></p><p dir="RTL">قد يؤثر هذا المنتج الطبي على ردود أفعالك وقدرتك على القيادة.<strong> </strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">قد تحدث الآثار الجانبية المحتملة للعلاج الكيميائي باستخدام بليومايسين فينوس، مثل الغثيان والقيء. إذا كنت تعاني من هذه الآثار الجانبية، فلا يجب عليك القيادة و / أو تشغيل الآلات التي تتطلب منك أن تكون متيقظًا ومنتبهًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم الطبيب بحساب الكمية المطلوبة لك، بناءً على تفاصيل الجرعة المحددة لاحقًا.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>الجرعة المعتادة:</u></p><p dir="RTL">تعتمد الجرعة (الإجمالية) على دواعي الاستعمال، وعمرك، ووظيفة الكلى، والجمع بين الأدوية الأخرى المضادة للسرطان. سيحدد طبيبك جرعة بليومايسين فينوس ومدة العلاج وعدد العلاجات. يمكن أن تختلف هذه الجرعات لكل مريض.</p><p>&nbsp;</p><p dir="RTL">هناك خطر لحدوث تفاعلات فرط حساسية خطيرة خاصة في مرضى سرطان الغدد الليمفاوية والتي قد تحدث مباشرة أو في وقت ما بعد تناول العلاج. لذلك، سوف يعطيك طبيبك جرعة اختبار وسيراقبك لمدة 4 ساعات قبل بدء العلاج بليومايسين فينوس لأول مرة.</p><p>&nbsp;</p><p dir="RTL"><u>طريقة الإعطاء</u></p><p dir="RTL">سيقوم طبيبك بإعطاء بليومايسين فينوس في الوريد أو الشريان، أو تحت الجلد، أو في العضلات، أو مباشرة في الورم، أو في المساحة الفارغة المحيطة بالرئتين (داخل الجافية)، إما عن طريق الحقن أو باستخدام التسريب.</p><p>&nbsp;</p><p dir="RTL"><strong>استخدام العلاج مع الأطفال والمراهقين</strong></p><p dir="RTL">لا توجد خبرة كافية فيما يتعلق باستخدام بليومايسين فينوس لدى الأطفال والمراهقين.</p><p dir="RTL">حتى يتم توفير مزيد من المعلومات، يجب إعطاء بليومايسين فينوس فقط للأطفال والمراهقين في ظروف استثنائية وفي مرافق خاصة.</p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;إذا تناولت بليومايسين فينوس أكثر مما ينبغي</strong></p><p dir="RTL">تشمل الأعراض التي يمكن أن تحدث إذا تناولت الكثير من البليوميسين: انخفاض ضغط الدم، والحمى، وزيادة معدل ضربات القلب، والصدمة. إذا لاحظت أيًا من الأعراض المذكورة أعلاه، فيرجى إخبار طبيبك الذي سيرتب لك العلاج المناسب.&nbsp; يجب التوقف عن استخدام المنتج الطبي على الفور.</p><p>&nbsp;</p><p dir="RTL">معلومات للطبيب:</p><p dir="RTL">يمكن العثور على معلومات حول علاج الجرعة الزائدة في نهاية هذه النشرة.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت تناول بليومايسين فينوس </strong></p><p dir="RTL">إذا فاتك حقنة، فالرجاء التحدث مع طبيبك المعالج ، لتوضيح الرغبة في وكيفية تعويض الجرعة الفائتة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول بليومايسين فينوس</strong></p><p dir="RTL">إذا توقفت فجأة عن تناول بليومايسين فينوس من دون استشارة الطبيب، فقد تتكرر الأعراض الأصلية.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p>&nbsp;</p><p dir="RTL">يمكن أن يسبب بليومايسين فينوس آثارًا جانبية فورية ومتأخرة.&nbsp; رد الفعل الأول هو الحمى في يوم الحقن. قد يحدث أيضًا فقدان الشهية، تساقط الشعر، قشعريرة، إرهاق، التهاب في الرئتين (التهاب رئوي خلالي) - ضيق في التنفس أو سعال، التهاب في الغشاء المخاطي للفم وغثيان. كما لوحظ ألم في مكان الحقن وفي منطقة الورم في بعض الأحيان. تشمل الآثار الجانبية المتفرقة الأخرى انخفاض ضغط الدم والتهاب الوريد الخثاري الموضعي (التهاب الوريد) بعد تناوله عبر الوريد.</p><p dir="RTL">التقرحات الجلدية وفي الأغشية المخاطية هي الآثار الجانبية الأكثر شيوعًا ويتم ملاحظتها في ما يصل إلى 50% من المرضى الخاضعين للعلاج. فهي تسبب الاحمرار؛ والطفح الجلدي، والشعور بالحكة، وتشكيل القرحة، وعلامات التمدد والبثور؛ والتصبغ الكثيف، وألم وتورم في أطراف الأصابع.</p><p>&nbsp;</p><p dir="RTL"><strong>أعراض جانبية خطيرة:</strong></p><p dir="RTL">إذا ظهرت لديك أي من الآثار الجانبية التالية، فأخبر طبيبك على الفور:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صوت طقطقة أو فرقعة عند التنفس</p><p>&nbsp;</p><p dir="RTL">قد تحتاج إلى إيقاف علاجك.</p><p>&nbsp;</p><p dir="RTL">يمكن أن تشمل الآثار الجانبية ما يلي:</p><p>&nbsp;</p><p dir="RTL"><strong>شائع جدًا </strong>(قد يؤثر على أكثر من 1 من كل 10 مرضى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب رئوي خلالي (التغيرات الالتهابية في الرئتين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التليف الرئوي (مرض يصيب أنسجة الرئة بسبب زيادة تكوين النسيج الضام بين الحويصلات الهوائية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استفراغ وغثيان</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغشاء المخاطي (التهاب الأغشية المخاطية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الفم (التهاب الغشاء المخاطي للفم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار التهابي للجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالحكة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخطوط (علامات التمدد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البثرات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط التصبغ (زيادة تكوين الصباغ)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم وانتفاخ في أطراف الأصابع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط التقرن (سماكة مفرطة للجلد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(قد تظهر لدى حتى 1 من كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية الشديدة. قد تحدث هذه التفاعلات على الفور، أو بعد فترة متأخرة لبضع ساعات بعد الجرعة الأولى أو الثانية. أخبر طبيبك على الفور إذا أصبت بأي أزيز مفاجئ، أو صعوبة في التنفس، أو تورم في الجفون، أو الوجه أو الشفتين، أو طفح جلدي أو حكة (تؤثر بشكل خاص على جسمك بالكامل). تفاعل خاص (أنواع مختلفة من تفاعلات فرط الحساسية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور تنفسي حاد (متلازمة الضائقة التنفسية الحادة - ARDS)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توقف التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانسداد الرئوي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، شرى، حُمامي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب (تصلب الجلد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم (بسبب احتباس السوائل في الأنسجة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى والقشعريرة والضيق</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong>(قد تظهر لدى حتى 1 من كل 100 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبت نقي العظم (تلف نخاع العظم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الكريات البيض (انخفاض في عدد خلايا الدم البيضاء)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة العدلات (انخفاض في الخلايا الحبيبية العدلات في الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الصفيحات (انخفاض في الصفائح الدموية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزف (نزيف)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتباك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الشفة الزاوي (التهاب زوايا الفم) والإسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوه الأظافر وتغير لونها وتشكيل الفقاعات عند نقاط الضغط</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات والمفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة البول (انخفاض إخراج البول)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أثناء التبول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوال (زيادة كمية البول)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتباس البول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في منطقة الورم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الوريد (التهاب الوريد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم (سماكة) جدار الوريد وانقباض الوصول الوريدي (عند التناول عبر الوريد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب (تصلب الأنسجة بعد تناوله في العضلات أو بالإعطاء الموضعي)</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة </strong>(قد تظهر لدى حتى 1 من كل 1000 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى قلة العدلات (حمى ناتجة عن انخفاض في خلايا الدم البيضاء)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبة القلبية والتهاب التامور (التهاب الكيس الليفي المحيط بالقلب) وألم في الصدر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى دماغية ، اعتلال الأوعية الدقيقة الخثاري (مرض الشعيرات الدموية والشرايين) ، متلازمة انحلال الدم الانحلالي (مرض شديد يصيب الدم والكلى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الشرايين الدماغية (التهاب الشرايين الصغيرة والمتوسطة الحجم في الدماغ)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظاهرة رينود (اضطراب الأوعية الدموية)، تجلط الشرايين، تجلط الأوردة العميقة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختلال كبدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب الجلد (تصلب النسيج الضام)</p><p>&nbsp;</p><p dir="RTL"><strong>شديدة الندرة </strong>(قد تظهر لدى حتى 1 من بين 10,000 شخص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة تحلل الورم (حالة بعد التحليل السريع للأورام)</p><p>&nbsp;</p><p dir="RTL"><strong>غير معروف </strong>(لا يمكن تقدير معدل التكرار من البيانات المتاحة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى شديدة (تعفن الدم)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حاد في خلايا الدم (قلة الكريات الشاملة)،</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدم الحمراء (فقر الدم)،</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p>&nbsp;</p><p dir="RTL">إذا تفاقمت أي من الآثار الجانبية، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، فيرجى إخبار طبيبك أو مقدم الرعاية الصحية أو الصيدلي لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="docshape2" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:59.7pt;margin-top:15.65pt;width:499.7pt;
  height:83.3pt;z-index:-15728640;visibility:visible;mso-wrap-style:square;
  mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
  mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText dir=RTL style='margin-top:0in;margin-right:12.1pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
     text-indent:-7.0pt;line-height:13.5pt;mso-line-height-rule:exactly;
     mso-list:l0 level1 lfo1;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>
     </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
     style='letter-spacing:-.1pt'>المركز الوطني للتيقظ الدوائي (NPC):</span><span
     dir=LTR><o:p></o:p></span></p>
     <p class=MsoBodyText dir=RTL style='margin-top:6.95pt;margin-right:7.0pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
     text-indent:-7.0pt;mso-list:l2 level1 lfo3;tab-stops:12.15pt;direction:
     rtl;unicode-bidi:embed'><![if !supportLists]><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
     dir=RTL></span><span lang=AR-SA style='letter-spacing:-.15pt'>مركز الاتصال
     بالهيئة العامة للغذاء والدواء على الرقم 19999 </span><span dir=LTR><o:p></o:p></span></p>
     <p class=MsoBodyText dir=RTL style='margin-top:6.85pt;margin-right:7.0pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
     text-indent:-7.0pt;mso-list:l2 level1 lfo3;tab-stops:12.15pt;direction:
     rtl;unicode-bidi:embed'><![if !supportLists]><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
     dir=RTL></span><span lang=AR-SA style='letter-spacing:-.05pt'>البريد
     الإلكتروني: </span><a href="mailto:npc.drug@sfda.gov.sa"><span dir=LTR
     style='color:blue;letter-spacing:-.1pt'>npc.drug@sfda.gov.sa</span></a><span
     dir=LTR><o:p></o:p></span></p>
     <p class=MsoBodyText dir=RTL style='margin-top:6.95pt;margin-right:7.0pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
     text-indent:-7.0pt;mso-list:l2 level1 lfo3;tab-stops:11.9pt;direction:
     rtl;unicode-bidi:embed'><![if !supportLists]><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
     dir=RTL></span><span lang=AR-SA style='letter-spacing:-.15pt'>الموقع
     الإلكتروني: </span><u style='text-underline:blue'><span lang=AR-SA
     style='color:blue;letter-spacing:-.1pt'>https://ade.sfda.gov.sa</span></u><span
     dir=LTR><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p dir="RTL">&middot; المركز الوطني للتيقظ الدوائي (NPC):</p><p dir="RTL">-&nbsp; مركز الاتصال بالهيئة العامة للغذاء والدواء على الرقم 19999</p><p dir="RTL">-&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">-&nbsp; الموقع الإلكتروني: <u>https://ade.sfda.gov.sa</u></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الكرتون أو القنينة بعد انتهاء الصلاحية.&nbsp; يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p>&nbsp;</p><p dir="RTL">يُحفظ في الثلاجة (2 درجة مئوية - 8 درجة مئوية).</p><p>&nbsp;</p><p dir="RTL">للاستخدام لمرة واحد فقط. تخلص من أي بقايا.</p><p>&nbsp;</p><p dir="RTL">يجب استخدام المنتج المعاد تكوينه/المخفف على الفور.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات واضحة للتلف في المنتج أو القارورة، على سبيل المثال، تغير لون المسحوق أو تلف القارورة والسدادة.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية.&nbsp; اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها.&nbsp; ستساعد هذه الإجراءات في حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محتويات بليومايسين فينوس</p><p dir="RTL">&bull;&nbsp; المادة الفعالة هي كبريتات البليوميسين.</p><p dir="RTL">&bull;&nbsp; المكون الآخر هو مانيتول وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>شكل بليومايسين فينوس وما هي محتويات العبوة</p><p dir="RTL">بليومايسين فينوس عبارة عن كتلة بيضاء أو كريمية اللون، مجففة بالتجميد مملوءة في قوارير زجاجية عديمة اللون سعة 5 مل ومغلقة بسدادة مطاطية محكمة الغلق بغطاء من الألومنيوم قابل للطي.</p><p dir="RTL">1 قارورة/عبوة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فينوس رديميز المحدودة</p><p dir="RTL">منطقة هيل توب الصناعية، جهارمجري، إي بي آي بي،</p><p dir="RTL">المرحلة الأولى (تحويلة)، بهاتولي كالان، بادي، مركز سولان ، هيماشال براديش، 173205،</p><p dir="RTL">الهند</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة لآخر مرة في يونيو 2023.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Bleomycin Venus (Bleomycin for Injection USP 15 Units)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains:
	Bleomycin Sulfate USP 
	equivalent to Bleomycin 15 Units

	For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Powder for solution for injection
	White or cream-colored, lyophilized mass.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bleomycin can be used in the treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Squamous cell carcinoma (SCC) of the head and neck, cervix and external genitalia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hodgkin&#39;s lymphoma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Hodgkin&rsquo;s lymphoma of intermediate and high malignancy in adults</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Testicular carcinoma (seminoma and non-seminoma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intrapleural therapy of malignant pleural effusions.</p><p>&nbsp;</p><p>Bleomycin can be used as a monotherapy, but is usually combined with other cytostatics and/or radiation therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><strong>Warning: </strong>Posology for all therapeutic indications is provided in IU and not in mg. Some hospital protocols may state use &ldquo;mg&rdquo; instead of Units (U or IU). This mg value refers to mg activity and not to mg-dry material as these reflect different values.</p><p>Our recommendation is to ignore this posology in mg and actually use the posology in International Units (IU) as described in this SmPC for the relevant therapeutic indications.</p><p>Please note that 1 mg dry substance is equivalent to at least 1500 IU. Yet we strongly recommend <strong><u>not to use</u> </strong>this conversion as this may result in over dosage because of the differences between mg-activity and mg-dry material. This product should therefore only be prescribed in international units (IU).</p><p>&nbsp;</p><p>Bleomycin should only be used under the strictest supervision of a physician specialised in the use of oncolytic medicinal products, preferably in a hospital with experience in such therapies</p><p>&nbsp;</p><p>Bleomycin may be administered intravenously, intramuscularly, intraarterially, subcutaneously or by intrapleural instillation. Local injection directly into the tumour may occasionally be indicated.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p>&nbsp;</p><p><em>Adults</em></p><p><em>&nbsp;</em></p><p><em>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Squamous cell carcinoma</em></p><p>Intramuscular or intravenous injection of 10-15 x 10<sup>3</sup> IU/m<sup>2</sup> body surface area (BSA), once or twice a week, at intervals of 3-4 weeks up to a lifetime cumulative dose of 360 x 10<sup>3</sup> IU.</p><p>Intravenous infusion of 10-15 x 10<sup>3</sup> IU/m<sup>2</sup>/day for 6-24 hours on 4 to 7 consecutive days, at intervals of 3-4 weeks.</p><p>&nbsp;</p><p><em>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Hodgkin&#39;s disease and non-Hodgkin&#39;s lymphoma</em></p><p>When used alone, intramuscular or intravenous injection of 5-15 x10<sup>3</sup> IU/m<sup>2</sup> BSA, once or twice a week, up to a cumulative total dose of 225 x10<sup>3</sup> IU. Because of the possibility of anaphylactoid reactions, lymphoma patients should be treated with lower doses (for instance 2 x10<sup>3 </sup>IU) for the first two applications. If there are no acute</p><p>reactions after 4 hours of observation, the normal dose schedule can be followed.</p><p>&nbsp;</p><p><em>3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Testicular tumours</em></p><p>Intramuscular or intravenous injection of 10-15 x10<sup>3</sup> IU/m<sup>2</sup> BSA once or twice a week, at intervals of 3-4 weeks up to a total cumulative dose of 400 x 10<sup>3</sup> IU.</p><p>The intravenous infusion of the dose of 10-15 x 10<sup>3</sup> IU/m<sup>2</sup> BSA/day is performed for 6-24 hours on 5-6 consecutive days, at intervals of 3-4 weeks.</p><p>&nbsp;</p><p><em>4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>Malignant pleural effusions</em></p><p>60 x 10<sup>3</sup> IU in 100 mL physiological saline solution intrapleurally, as a single dose, which can be repeated after 2-4 weeks, depending on the response. Since approximately 45% of bleomycin is absorbed, this should be taken into account for the lifetime cumulative dose (body surface area, kidney function and lung function).</p><p>&nbsp;</p><p>The development of stomatitis is the most useful guide to the determination of individual tolerance with respect to the maximum dose. A total cumulative dose of 400 x10<sup>3</sup> IU (corresponding to 225 x 10<sup>3</sup> IU/m<sup>2</sup> BSA) should not be exceeded in patients under 60, because of the increased risk of pulmonary toxicity in all indications. In lymphoma patients, the total dose should not be more than 225 x10<sup>3</sup>IU.</p><p>In cases of Hodgkin&#39;s disease and testicular tumours, improvement occurs rapidly and can be observed within two weeks. If no improvement is observed by then, an improvement is unlikely. Squamous cell carcinomas respond more slowly. In some cases it can take up to three weeks before an improvement is observed.</p><p>&nbsp;</p><p><em>Elderly population (from the age of 60)</em></p><p><em>&nbsp;</em></p><p>The total dose of bleomycin in elderly patients should be reduced according to the following table:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Age in years</p></td><td style="vertical-align:top"><p>Total dose</p></td><td style="vertical-align:top"><p>Dose per week</p></td></tr><tr><td style="vertical-align:top"><p>80 and over</p></td><td style="vertical-align:top"><p>100 x 10<sup>3</sup> IU</p></td><td style="vertical-align:top"><p>15 x 10<sup>3</sup> IU</p></td></tr><tr><td style="vertical-align:top"><p>70-79</p></td><td style="vertical-align:top"><p>150-200 x 10<sup>3</sup></p><p>IU</p></td><td style="vertical-align:top"><p>30 x 10<sup>3</sup> IU</p></td></tr><tr><td style="vertical-align:top"><p>60-69</p></td><td style="vertical-align:top"><p>200-300 x 10<sup>3</sup></p><p>IU</p></td><td style="vertical-align:top"><p>30-60 x 10<sup>3</sup> IU</p></td></tr><tr><td style="vertical-align:top"><p>Under 60</p></td><td style="vertical-align:top"><p>400 x 10<sup>3</sup> IU</p></td><td style="vertical-align:top"><p>30-60 x 10<sup>3</sup> IU</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>There is insufficient experience with regard to the administration of bleomycin in paediatric patients. Until more information is available, bleomycin should only be administered in children in exceptional circumstances and at special facilities. If administration is indicated as part of a combination regimen the dosage is usually calculated based on the body surface area and adjusted to meet the individual requirements of each patient. Current specialized protocols and guidelines should be consulted for the appropriate treatment regimen.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>In case of renal failure, especially if creatinine clearance &lt;35 ml / min, elimination of bleomycin is delayed. There are no specific guidelines for dose adjustment in these patients, but it is recommended that patients with moderate renal impairment (GFR 10-50 ml / min) should receive 75% of the usual dose administered at the usual dosing intervals and patients severe renal failure (GFR below 10 ml / minute) should receive 50 % of the usual dose, given at the normal dosing interval. No dose adjustment is required in patients with a GFR greater than 50 ml / minute.</p><p>&nbsp;</p><p><em><u>Combination therapy</u></em></p><p>The dose might require adjustment when bleomycin is used in combination therapy.</p><p>The bleomycin dosage should be reduced in conjunction with radiotherapy since the risk of mucosal damage is increased. Dose adjustment may also be required when bleomycin is used in combination chemotherapy.</p><p>Details regarding treatment regimens applied for certain indications can be found in the current literature.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><strong><em>Method of administration and preparation of the solution for injection/infusion (see also section 6.6)</em></strong></p><p>N.B.: The entire contents of a vial (15000 IU) should be dissolved in the appropriate quantity of solvent for preparation of the solution. The quantity of units required for the treatment is then taken from this solution.</p><p>&nbsp;</p><p><u>Intramuscular injection</u></p><p>Dissolve the contents of a vial in 1-5 mL physiological saline solution. Since repeated i.m. injections at the same site can cause local discomfort, it is recommended to change the injection site regularly. In the event of excessive local discomfort, a local anaesthetic can be added to the injection solution, e.g. 1.5-2 mL lidocaine HCl 1%.</p><p>&nbsp;</p><p><u>Intravenous injection</u></p><p>Dissolve the contents of a vial in 5-10 mL physiological saline solution and inject slowly over a period of 5-10 minutes. Fast bolus injections are to be avoided, because they lead to high intrapulmonary plasma concentrations, increasing the risk of lung damage.</p><p>&nbsp;</p><p><u>Intravenous infusion</u></p><p>Dissolve the contents of a vial in 200-1,000 mL physiological saline solution.</p><p>&nbsp;</p><p><u>Intra-arterial injection</u></p><p>Dissolve the contents of a vial of bleomycin in at least 5 mL physiological saline solution and inject over a period of 5-10 minutes.</p><p>&nbsp;</p><p><u>Intra-arterial infusion</u></p><p>Dissolve bleomycin in 200-1,000 mL physiological saline solution. The infusion can be administered over a few hours to a number of days. Heparin can be added to prevent thrombosis at the injection site, especially if the infusion is administered over a longer period.</p><p>&nbsp;</p><p>Injection or infusion into an artery supplying the tumour tends to exhibit higher efficacy than other systemic routes of administration. The toxic effects are the same as with intravenous injection or infusion.</p><p>&nbsp;</p><p><u>Subcutaneous injection</u></p><p>Dissolve the contents of a vial in maximum 5 mL physiological saline solution. Absorption following subcutaneous injection is delayed and may resemble a slow i.v. infusion; this form of administration is rarely used. Care must be taken to avoid intradermal injection.</p><p>&nbsp;</p><p><u>Intratumoural injection</u></p><p>Bleomycin is dissolved in physiological saline solution, producing a concentration of 1-3 x10<sup>3</sup> IU/mL; this solution is then injected into the tumour and the surrounding tissue.</p><p>&nbsp;</p><p><u>Intrapleural instillation</u></p><p>Following drainage of the pleural cavity, bleomycin, dissolved in 100 ml physiological saline solution, is instilled via the puncture cannula or drainage catheter. The cannula or catheter is then removed. In order to ensure uniform distribution of the bleomycin in the serous cavity, the position of the patient should be changed every 5 minutes for a period of 20 minutes. Approximately 45 % of Bleomycin will be absorbed; this has to be considered for the total dose (body surface area, kidney function, lung function).</p><p>&nbsp;</p><p>Perivascular administration of bleomycin does not usually require any specific measures. If in doubt (highly concentrated solution, sclerotic tissue, etc.) perfusion can be performed with a physiological saline solution.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or any of the excipients listed in section 6.1.
-	Ataxia telangiectasia
-	Pulmonary infection, severely impaired lung function or a history of lung damage caused by bleomycin.
-	Breastfeeding (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients receiving Bleomycin chemotherapy must be carefully monitored by experienced oncologists.</p><p>&nbsp;</p><p>A highly rigorous risk/benefit assessment should be performed following lung or mediastinal radiotherapy. Bleomycin should only be used with caution and at a reduced dose in the event of impaired renal function. Because of the possible mutagenic effects of bleomycin on male and female germ cells, reliable contraception must be ensured during therapy and for up to 6 months after the end thereof.</p><p>&nbsp;</p><p><u>Pulmonary reactions</u></p><p>Patients should be carefully monitored for any signs of pulmonary dysfunction during treatment with bleomycin.</p><p>&nbsp;</p><p>Pulmonary reactions are the most serious side effects, occurring in roughly 10% of patients treated, during or after the end of a course of treatment. The most common form is interstitial pneumonitis. If this condition is not recognised and treated promptly, it can develop into pulmonary fibrosis. Approximately 1% of patients treated have died from the consequences of pulmonary fibrosis.</p><p>&nbsp;</p><p>Patients undergoing treatment with bleomycin should have chest X-rays weekly. These should continue to be taken for up to 4 weeks after completion of the course and patients should be kept under clinical review for approximately 2 months. With concomitant radiation therapy of the thorax, a study or an X-ray of the thorax should possibly be done more frequently.</p><p>&nbsp;</p><p>Lung function tests with 100% oxygen should not be used in patients who have been treated with bleomycin. Lung function tests using less than 21% oxygen are recommended as an alternative. Monthly analysis of pulmonary diffusion capacity for carbon monoxide could be planned. A study of lung function, in particular the measuring of the carbon monoxide diffusion and vital capacity, often makes an early diagnosis of lung toxicity possible.</p><p>&nbsp;</p><p>Pulmonary toxicity is both dose-related and age-related, occurring more frequently in those over the age of 70 and in patients who have received a total dose of more than 400 units. It is significantly increased by thoracic irradiation and by hyperoxia during surgical anaesthesia.</p><p>&nbsp;</p><p>Pulmonary toxicity has also been observed on occasion in young patients receiving low doses.</p><p>&nbsp;</p><p>Vascular changes occur in the lungs, leading to partial destruction of the elasticity of the vessel wall. The earliest symptom of pulmonary damage caused by bleomycin is dyspnoea. Fine rales are the earliest sign. If pulmonary changes are noticed, bleomycin treatment should be discontinued until it is determined whether they are caused by the medication. The patients should be treated with broad spectrum antibiotics and corticosteroids.</p><p>&nbsp;</p><p>In the event of dyspnoea, cough, basal crepitations or lung infiltrates not clearly attributable to the neoplasm or a concomitant pulmonary disease, administration of bleomycin must be discontinued immediately and the patient should be treated with a corticosteroid and broad-spectrum antibiotics. High oxygen concentrations should be used with caution. In case of lung damage as a result of bleomycin, bleomycin should not be administered any more (see section 4.3).</p><p>&nbsp;</p><p>Although the pulmonary toxicity of bleomycin appears to be dose-related upon exceeding a total dose of 400 units (corresponding to approx. 225 units/m<sup>2</sup> BSA), it can also be observed at lower doses, in particular in elderly patients, patients with impaired renal function, patients with pre-existing lung disease, patients with a history of or receiving concomitant thoracic radiotherapy, and patients requiring oxygen administration. These patients should be carefully monitored and the bleomycin dosage reduced or the dose interval prolonged based on clinical observation of the patient. Bleomycin should be used with extreme caution in patients with lung cancer as these patients show an increased incidence of pulmonary toxicity<em>.</em></p><p><em>&nbsp;</em></p><p>As 2/3 of the administered dose of bleomycin is excreted unchanged in the urine, renal function has a major effect on the rate of excretion. Plasma concentrations are significantly elevated when usual doses are administered to patients with renal function disorders.</p><p>&nbsp;</p><p>Other clinical conditions requiring caution include patients with severe heart disease or hepatic dysfunction as toxicity may be increased and patients with varicella as fatal systematic dysfunctions may occur.</p><p>&nbsp;</p><p><u>Idiosyncratic reactions/ hypersensitivity</u></p><p>Idiosyncratic reactions, clinically similar to anaphylaxis, have been reported in approximately 1% of lymphoma patients treated with bleomycin. The reaction may be immediate or after a few hours delay, and usually occurs after the first or second dose. It consists of hypotension, confusion, fever, chills, wheezing and stridor.</p><p>Treatment is symptomatic and comprises volume expansion, vasopressors, antihistamines and corticosteroids.</p><p>&nbsp;</p><p>Because of the possibility of an anaphylactoid reaction (in 1% of lymphoma patients, according to the literature), patients should initially receive a test dose of 1-2 units. If there is no acute reaction, the full dose can be administered.</p><p>&nbsp;</p><p><u>Miscellaneous</u></p><p>There have been reports of vascular toxicity following use of bleomycin, in particular in combination with other antineoplastic agents. The events are clinically heterogeneous and include myocardial infarction, cerebrovascular insults, thrombotic microangiopathies, e.g. haemolytic uraemic syndrome and cerebral arteritis.</p><p>In adults or adolescents capable of reproduction, effects on the sexual glands should be considered.</p><p>&nbsp;</p><p>Like other cytotoxic active substances, bleomycin can trigger tumour lysis syndrome in patients with rapidly growing tumours. Appropriate supportive treatment and pharmacological measures might prevent or alleviate such complications.</p><p>&nbsp;</p><p>Patients with creatinine clearance values of less than 50 mL/min should be treated with caution and their renal function should be carefully monitored during the administration of bleomycin. Lower doses of bleomycin may be required in these patients than those with normal renal function (see section 4.2).</p><p>&nbsp;</p><p><u>Intravenous administration</u></p><p>Vascular pain may occur, therefore, it is important to pay due attention to concentration of the injection and administration rate. Give intravenously as slowly as possible.</p><p>&nbsp;</p><p><u>Intramuscular administration</u></p><p>Avoid repeated injections at the same site and innervated sites, particularly if administering to paediatrics. If insertion of the injection needle evokes intense pain or if blood flows back into the syringe, withdraw the needle immediately and inject at a different site.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Combination chemotherapy</em></p><p>If bleomycin is used as part of combination chemotherapy, its toxicity should be taken into account for the selection and dosage of other agents with a similar toxicity spectrum.</p><p>&nbsp;</p><p>An increased risk of pulmonary toxicity has been reported with concomitant administration of other agents with pulmonary toxicity, e.g. BCNU, mitomycin, cyclophosphamide, methotrexate and gemcitabine. The pulmonary toxicity of bleomycin is potentiated by combined treatment with cisplatin in particular. Special care should therefore be taken with this combination. Data from the literature indicates that cisplatin should only be administered after bleomycin.</p><p>&nbsp;</p><p>In patients with testicular tumours treated with a combination of bleomycin and vinca alkaloids, Raynaud- like phenomena have been reported with acral ischemia, leading to necrosis of peripheral parts of the body (fingers, toes, tip of the nose).</p><p>&nbsp;</p><p>In patients who received a combination therapy of cisplatin, vinblastine and bleomycin, a positive correlation was observed between GFR (glomerular filtration rate) and lung function. Bleomycin should therefore be used with caution in severe renal impairment patients. It was revealed in another study that increasing cisplatin doses were associated with a decrease in creatinine clearance and therefore in the elimination of bleomycin.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Radiotherapy</em></p><p>Previous or concurrent thoracic radiotherapy contributes significantly to increased frequency and severity of pulmonary toxicity.</p><p>&nbsp;</p><p>Previous or concurrent radiotherapy to the head or neck is a factor increasing stomatitis and angular stomatitis may deteriorate. It may cause inflammation of pharyngolaryngeal mucosa infrequently resulting in hoarseness.</p><p>&nbsp;</p><p><em>Oxygen concentration</em></p><p>Because of bleomycin&#39;s potential to sensitise the lung tissue, pulmonary toxicity increases if bleomycin is administered during surgical procedures involving increased oxygen supply. The inspiratory O<sub>2</sub> concentration should therefore be reduced intraoperatively and postoperatively.</p><p>&nbsp;</p><p><em>Granulocyte Colony-Stimulating Factor (GCSF)</em></p><p>An increase in the number of neutrophil granulocytes and stimulation of the ability to generate free oxygen radicals following administration of GCSF may potentiate lung injury.</p><p>&nbsp;</p><p><em>Digoxin</em></p><p>These are case reports of a reduced effect of digoxin as a result of a reduced oral bioavailability when combined with bleomycin.</p><p>&nbsp;</p><p><em>Phenytoin and phosphophentoin</em></p><p>There are case reports of reduced levels of phenytoin when combined with bleomycin. Risk of exacerbation of convulsions resulting from the decrease of phenytoin digestive absorption by cytotoxic medicinal products or risk of toxicity enhancement or loss of efficacy of the cytotoxic medicinal product due to increased hepatic metabolism by phenytoin. Concomitant use is not recommended.</p><p>&nbsp;</p><p><em>Clozapine</em></p><p>Concomitant use of bleomycin with clozapine should be avoided due to an increased risk of agranulocytosis.</p><p>&nbsp;</p><p><em>Antibiotics</em></p><p>The bacteriostatic efficacy of gentamicin, amikacin and ticarcillin may be reduced.</p><p>&nbsp;</p><p><em>Ciclosporine, tacrolimus</em></p><p>Excessive immunosuppression with risk of lymphoproliferation exists.</p><p>&nbsp;</p><p><em>Live vaccines</em></p><p>The administration of live vaccines may lead to serious or life-threatening infections in patients whose immune system is weakened by chemotherapy agents, including bleomycin. Vaccinations with live vaccine should be avoided in patients receiving bleomycin. Use an inactivated vaccine where this exists (poliomyelitis). Vaccination with the yellow fever vaccine has resulted in severe and fatal infections when used in combination with immunosuppressive chemo therapeutics. This risk is increased in subjects who are already immunosuppressed by their underlying disease. This combination must not be used.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are insufficient data on the use of bleomycin in pregnant women. Studies in animals have shown reproduction toxicity (see section 5.3). On the basis of the results of animal studies and the pharmacological efficacy of the product, there is a potential risk of embryonic and foetal abnormalities. Bleomycin will pass the placenta.</p><p>Bleomycin should therefore not be used during the pregnancy, unless it is strictly necessary, particularly during the first trimester.</p><p>If pregnancy occurs during treatment, the patient should be informed about the risks for the unborn child and be monitored carefully. The possibility of genetic counselling should be considered.</p><p>&nbsp;</p><p><em>Women of childbearing potential/contraception in males and females</em></p><p>Both male and female patients should take adequate contraceptive measures up to six months after the discontinuation of the therapy.</p><p>Genetic counselling is also recommended for patients wishing to have children after therapy. Advice on conservation of sperm should be sought prior to treatment because of the possibility of irreversible infertility due to therapy with bleomycin.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown if Bleomycin or the metabolites are excreted in the mother&rsquo;s milk. Due to possible very harmful effects on the infant, breast-feeding during treatment with bleomycin is contraindicated.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Bleomycin therapy may cause irreversible infertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Possible side effects of chemotherapy with bleomycin, e.g. nausea and vomiting, may indirectly affect the patient&#39;s ability to drive or use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a.&nbsp;&nbsp;&nbsp; <u>Summary of the safety profile</u></p><p>Like most cytotoxic agents, bleomycin can cause immediate and delayed toxic effects. Fever on the day of injection is the earliest reaction. The most frequently observed adverse reactions in 1613 patients receiving bleomycin were pulmonary manifestations such as interstitial pneumonia or pulmonary fibrosis (10.2%), sclerosis of skin, pigmentation (40.6%), fever and rigors (39.8%), alopecia (29.5%), anorexia and weight decrease (28.7%), general malaise (16.0%), nausea and vomiting (14.6%), stomatitis (13.3%) and nail changes (11.2%). Pain at the injection site and in the tumour area has also been observed on occasion. Other sporadic side effects include hypotension and local thrombophlebitis following intravenous injection.</p><p>&nbsp;</p><p>There have also been reports of Raynaud&#39;s phenomena, both when using bleomycin as monotherapy and in combination therapy.</p><p>&nbsp;</p><p>&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp; <u>Tabulated list of adverse reactions</u></p><p>The following undesirable effects can occur during treatment with bleomycin:</p><p>&nbsp;</p><p>Frequencies are defined as follows:</p><p>Very common (&ge; 1/10), common (&ge; 1/100, &lt;1/10), uncommon (&ge; 1/1,000 to</p><p>&lt;1/100), rare (&ge; 1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000), Not known (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Primary system organ classes</strong></p></td><td style="vertical-align:top"><p><strong>Very </strong><strong>common</strong></p><p>&ge; <strong>1/10</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>&ge; <strong>1/100 -&lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&ge; <strong>1/1,000 -</strong></p><p><strong>&lt; 1/100</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>&ge; <strong>1/10,000 -</strong></p><p><strong>&lt; 1/1,000</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p><strong>&lt; 1/10,000</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sepsis</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms, Benign, Malignant and Unspecified (including Cysts and Polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tumour pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myelosuppression,</p><p>Leukopaenia, Neutropaenia, Thrombocytopaenia, Haemorrhage</p></td><td style="vertical-align:top"><p>Febrile neutropaenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancytopeni a, Anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylaxis, Hypersensitivity, Idiosyncratic drug reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Dizziness, Confusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial infarction, Pericarditis, Chest pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Cerebral infarction, Thrombotic microangiopa thies, Haemolytic uraemic syndrome, Cerebral arteritis, Raynaud&#39;s phenomena, Arterial thrombosis, Deep vein thrombosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Peripheral ischaemia</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Interstitial pneumonitis, Pulmonary fibrosis, Dyspnoea</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome (ARDS),</p><p>Lung failure, Pulmonary embolism</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Decreased appetite, Weight loss, Nausea, Vomiting, Mucositis, Stomatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angular cheilitis, Diarrhoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic impairment</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Erythema, Pruritus, Striae, Blistering, Hyperpigmentation, Tenderness and swelling of the fingertips, Hyperkeratosis,</p><p>Hair loss</p></td><td style="vertical-align:top"><p>Exanthema, Urticaria, Skin reddening, Induration, Oedema, Flagellate dermatitis</p></td><td style="vertical-align:top"><p>Deformation and discolouration of the nails,</p><p>Bulla formation at pressure points</p></td><td style="vertical-align:top"><p>Scleroderma</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle and joint pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oliguria, Dysuria, Polyuria, Urinary retention</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pyrexia, Chills,</p><p>Malaise</p></td><td style="vertical-align:top"><p>Pain in the tumour area, Phlebitis, Hypertrophy of the vein wall and venous access constriction (with i.v. administration), Induration (with i.m. or local administration)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tumour lysis syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>c.&nbsp; <u>Description of selected adverse reactions</u></p><p>Fever and chills may develop with a lag time of 45 hours or more after the administration of this drug. Because a dose response relation exists between the fever and dose at a given time, if the fever is severe, appropriate measures should be taken such as administering a reduced dose at shorter intervals, or antihistaminic and antipyretic agents before and/or after administration of this drug.</p><p>&nbsp;</p><p>If cutaneous side effects occur in AIDS patients, the treatment should be discontinued and not resumed. Skin and mucosal lesions are the most common undesirable effects and are observed in up to 50% of the patients treated. They comprise induration, oedema, erythema, pruritus, rashes, striae, ulceration, blistering, hyperpigmentation, tenderness, swelling of the fingertips, hyperkeratosis, nail changes, bulla formation at pressure points such as the elbows, hair loss and stomatitis.</p><p>&nbsp;</p><p>Mucosal ulcers appear to be aggravated by the combination of bleomycin with radiotherapy or other medication toxic to mucous membranes. Skin toxicity occurs at a relatively late stage and is correlated with the total dose; it usually develops in the second and third week after administration of 150 to 200 units of bleomycin.</p><p>&nbsp;</p><p>Gastrointestinal side effects such as nausea and vomiting are possible, but are observed more frequently in high-dose regimens. Antiemetics may be helpful. Loss of appetite and weight loss are common and may continue for a long time after the end of the treatment.</p><p>&nbsp;</p><p><u>Bone marrow</u></p><p>Bleomycin does not appear to have any significant bone marrow depressant properties. Thrombocytopaenia occurring in connection with bleomycin treatment has not been attributed to decreased production of platelets, but rather to increased destruction of platelets.</p><p>&nbsp;</p><p><u>To report any side effect(s): </u></p><p><strong>&nbsp;&nbsp; Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>&nbsp;&nbsp; Other GCC States:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific antidote. It is virtually impossible to eliminate bleomycin from the body by dialysis.</p><p>The acute reaction following an overdose consists of hypotension, fever, tachycardia, and generalised shock. Treatment is exclusively symptomatic. In the event of respiratory complications, the patient should be treated with a corticosteroid and a broad-spectrum antibiotic. Usually the lung reaction to an overdose (fibrosis) is not reversible, unless diagnosed at an early stage.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Cytotoxic antibiotics and related substances</p><p>ATC code: L01DC01</p><p>&nbsp;</p><p>Bleomycin is a mixture of basic, water-soluble glycopeptide-antibiotics with cytotoxic activity. Bleomycin acts by interacting with both single and double-stranded DNA (deoxyribonucleic acid) leading to both single and double-strand scission, which leads in turn to inhibition of cell division, inhibition of growth and inhibition of DNA synthesis. Bleomycin can also influence RNA (ribonucleic acid) and protein biosynthesis to a lesser extent.</p><p>&nbsp;</p><p>The main factor in the tissue selectivity of Bleomycin is differences in intracellular inactivation. Squamous cells, with their low bleomycin hydrolase content, are highly sensitive to Bleomycin. Chromosome aberrations such as fragmentation, chromatid breaks, and translocations occur in sensitive tissues, both healthy and neoplastic.</p><p>&nbsp;</p><p>Bleomycin can be pyrogenic. It causes little or no bone-marrow toxicity and no immunosuppression.</p><p>&nbsp;</p><p>Bleomycin can be used alone, or in combination with radiotherapy or other cytotoxic agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Bleomycin is absorbed to a very limited extent orally. Following intravenous bolus injection of 15 x 10<sup>3</sup> IU/m<sup>2</sup> BSA, peak plasma concentrations of 1-10 IU are reached after approximately 10 minutes. Following i.m. injection of 15 x 10<sup>3</sup> IU, maximum plasma levels of approximately 1 IU are reached after 30 minutes. Continuous infusion of 30 x 10<sup>3</sup> IU of bleomycin over 4-5 days results in an average steady-state plasma concentration of 1-3 IU/mL.</p><p>Following intrapleural or intraperitoneal administration, bleomycin is systemically absorbed. Following intrapleural administration, approximately 45% of the dose is absorbed into the circulation.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Bleomycin is rapidly distributed to the tissue, with the highest concentrations accumulating in the skin, lungs, peritoneum and lymph nodes. Low concentrations are found in the bone marrow. Bleomycin is not detectable in the cerebrospinal fluid following intravenous injection. Bleomycin crosses the placental barrier. The apparent volume of distribution (V <sub>d</sub>)<sub>&szlig;</sub> is assumed to be approx. 0.27 +/- 0.09 L/kg.</p><p>Bleomycin only binds to plasma proteins to a limited extent.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>The inactivation is performed by hydrolases, which have been detected in the plasma, liver, spleen, intestine and bone marrow. In contrast, the enzymatic activity of the hydrolases is low in the skin and lungs.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The elimination half-life (T &frac12; <sub>&szlig;</sub>) is approx. 3 hours after intravenous administration of a bolus injection. Two phases of elimination occur, a brief initial phase (t1/2&alpha;; 24 min.) followed by a longer terminal phase (t1/2&beta;; 2&ndash;4 hours). After continuous i.v. infusion, the elimination half-life may increase to 9 hours. The systemic plasma clearance (Cls) is approximately 1.1 mL/min/kg bw. Approximately 2/3 of the dose administered is excreted unchanged in the urine, probably by glomerular filtration.</p><p>&nbsp;</p><p>After an i.v. or i.m. injection, approximately 50% of the active substance is recovered in the urine. The half-life is considerably prolonged in patients with impaired renal function, to the extent that dose reductions are required. With a creatinine clearance of 35 mL/min, the renal excretion decreases to below 20% with the risk of increased plasma levels. Previous observations indicate that bleomycin is difficult to dialyze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal experiments have demonstrated teratogenic, mutagenic and carcinogenic properties for bleomycin. Mutagenic effects in humans are expected at clinically relevant exposure levels.</p><p>With respect to reproduction toxicity various effects were observed in mice and rats. In rabbits no teratogenicity was observed. In the mouse the female reproductive cells were more sensitive to the cytotoxic and mutagenic effects of bleomycin than the male cells.</p><p>Chromosomal abnormalities were observed in human bone marrow cells. The meaning of this for the embryonic/ foetal development in humans is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bleomycin should not be mixed with solutions of essential amino acids, riboflavin, ascorbic acid, dexamethasone, aminophylline, benzylpenicillin, carbenicillin, cefalotine, cefazoline, diazepam, furosemide, glutathione, hydrogen peroxide, hydrocortisone Na succinate, methotrexate, mitomycin, nafcillin, penicillin G, substances containing sulphydryl groups, terbutaline, or thiols. As bleomycin forms chelating agents with bi- and tervalent cations it should not be mixed with solutions that contain such ions (in particular copper)</p><p>&nbsp;</p><p>With the exception of the medicinal products specified under section 6.6 (&ldquo;Special precautions for disposal and other handling&rdquo;), this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
2 years.

The reconstituted/diluted product should be used immediately.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C).</p><p>For storage conditions after reconstitution/dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 ml colourless glass vials with rubber closure and aluminium cap containing lyophilized mass of bleomycin sulfate equivalent to Bleomycin 15 Units.</p><p>1 vial/pack</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single use only, the reconstituted solution is a clear pale yellow solution. Any unused solution should be discarded.</p><p>&nbsp;</p><p><u>Safe handling:</u></p><p>The general guidelines for safe handling of cytotoxic medicinal products must be adhered to. Appropriate precautions should be taken to avoid contact with the skin, mucous membranes and eyes. In the event of contamination, the parts affected should be washed thoroughly with water.</p><p>Urine produced for up to 72 hours after administration of bleomycin should be handled wearing protective clothing.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local regulations.</p><p>&nbsp;</p><p><u>Instructions for preparation of the solution for injection/infusion:</u></p><p>&nbsp;</p><p>The entire contents of a vial (15 x 10<sup>3</sup> IU) should be dissolved in the appropriate quantity of solvent for preparation of the solution. The quantity of IU required for the treatment is then taken from this solution.</p><p>&nbsp;</p><p><u>Intramuscular injection</u></p><p>Dissolve the contents of a vial in 1-5 mL physiological saline solution. In the event of excessive local discomfort, a local anaesthetic can be added to the injection solution,</p><p>e.g. 1.5-2 mL lidocaine HCl 1%.</p><p>&nbsp;</p><p><u>Intravenous injection</u></p><p>Dissolve the contents of a vial in 5-10 mL physiological saline solution.</p><p>&nbsp;</p><p><u>Intravenous infusion</u></p><p>Dissolve the contents of a vial in 200-1,000 mL physiological saline solution.</p><p>&nbsp;</p><p><u>Intra-arterial injection</u></p><p>Dissolve the contents of a vial of bleomycin in at least 5 mL physiological saline solution.</p><p>&nbsp;</p><p><u>Intra-arterial infusion</u></p><p>Dissolve bleomycin in 200-1,000 mL physiological saline solution. Heparin can be added to prevent thrombosis at the injection site, especially if the infusion is administered over a longer period.</p><p>&nbsp;</p><p><u>Subcutaneous injection</u></p><p>Dissolve the contents of a vial in maximum 5 mL physiological saline solution. Absorption following subcutaneous injection is delayed and may resemble a slow i.v. infusion; this form of administration is rarely used. Care must be taken to avoid intradermal injection.</p><p>&nbsp;</p><p><u>Intrapleural instillation</u></p><p>Following drainage of the pleural cavity, bleomycin dissolved in 100 mL physiological saline solution, is instilled via the puncture cannula or drainage catheter. The cannula or catheter is then removed. In order to ensure uniform distribution of the bleomycin in the serous cavity, the patient&#39;s position should be changed over 20 minutes at an interval of 5 minutes.</p><p>&nbsp;</p><p><u>Intratumoural injection</u></p><p>Bleomycin is dissolved in physiological saline solution, producing a concentration of 1-3 X 10<sup>3</sup> IU/mL.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Venus Remedies Limited
Hill Top Industrial Estate, Jharmajri EPIP,
Phase-I (Extn.), Bhatoli Kalan, Baddi, Distt. Solan, Himachal Pradesh, 173205
India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2023 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>